Bomedemstat
Bomedemstat (pronounced boh-med-em-stat) is a small molecule inhibitor of the enzyme lysine-specific demethylase 1 (LSD1) that is currently under investigation for its potential use in the treatment of myelofibrosis and other myeloproliferative neoplasms (MPNs).
Etymology
The name "Bomedemstat" is derived from the combination of the words "Bo" (short for Boehringer Ingelheim, the pharmaceutical company that first developed the drug), "med" (short for medicine), and "stat" (a common suffix in drug nomenclature indicating inhibition or stopping).
Pharmacology
Bomedemstat works by inhibiting the enzyme LSD1, which is involved in the regulation of gene expression. By inhibiting LSD1, Bomedemstat can potentially alter the abnormal gene expression patterns seen in MPNs, thereby slowing or stopping the progression of the disease.
Clinical Trials
Bomedemstat is currently in Phase 2 clinical trials for the treatment of myelofibrosis and other MPNs. Preliminary results have shown promise, with some patients experiencing a reduction in symptoms and an improvement in quality of life.
Related Terms
- Lysine-specific demethylase 1 (LSD1)
- Myelofibrosis
- Myeloproliferative neoplasms (MPNs)
- Boehringer Ingelheim
- Phase 2 clinical trials
See Also
External links
- Medical encyclopedia article on Bomedemstat
- Wikipedia's article - Bomedemstat
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski